NCT05738668|Unknown
Clinical-immunological Features of Anti-NMDAR Encephalitis
Bio-NMDAr
Loading search results
Bio-NMDAr
Sponsor study identifier
observational
400
1 country
1
Study Start
February 1, 2022
Actual (reported)Primary Completion
October 1, 2022
Actual (reported)Study Completion
February 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Using a retrospective cohort of 501 patients with anti-NMDAR encephalitis to assess clinical and immunological prognostic biomarkers
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 1, 2022
Actual (reported)September 5, 2022
Actual (reported)October 1, 2022
Actual (reported)February 22, 2023
Actual (reported)February 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Modified Rankin scale (mRS)
Scale for measuring the degree of dependence in the daily activities of people who have suffered of neurological disability. 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. \- Moderate disability. Requires some help, but able to walk unassisted. 4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. \- Dead.
Baseline
Patients with well-characterized anti-NMDAR encephalitis.
This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of "good clinical practice" in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the "Centre de Ressources Biologiques des Hospices Civils de Lyon" (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with well-characterized anti-NMDAR encephalitis
Hôpital Neurologique Pierre Wertheimer / Groupement Hospitalier Est
Lyon, BRON, 69677, France
Blood, DNA, cells, CSF collected at diagnosis time
First Submitted
September 5, 2022
First Posted
February 22, 2023
Study Start
February 1, 2022
Actual (reported)Primary Completion
October 1, 2022
Actual (reported)Contact the study team to confirm eligibility.
Study Completion
February 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
February 22, 2023
Record last verified: 2022-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: